Atea Pharmaceuticals Inc Stock
Atea Pharmaceuticals Inc Stock price
Key metrics
| Market capitalization | $287.17m |
| Enterprise Value | $-193.80m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 1.53 |
| P/B ratio (TTM) P/B ratio | 0.63 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-200.50m |
| Free Cash Flow (TTM) Free Cash Flow | $-126.94m |
| Cash position | $482.81m |
Is Atea Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Atea Pharmaceuticals Inc Stock Analysis
Analyst Opinions
4 Analysts have issued a Atea Pharmaceuticals Inc forecast:
Analyst Opinions
4 Analysts have issued a Atea Pharmaceuticals Inc forecast:
Financial data from Atea Pharmaceuticals Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.42 -0.42 |
0%
0%
|
|
| EBITDA | -200 -200 |
27%
27%
|
EBIT (Operating Income) EBIT | -200 -200 |
27%
27%
|
| Net Profit | -174 -174 |
33%
33%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Atea Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Atea Pharmaceuticals Inc Stock News
Company Profile
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Jean-Pierre Sommadossi |
| Employees | 75 |
| Founded | 2012 |
| Website | www.ateapharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
